Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease
✍ Scribed by Elisa Garbayo; Eduardo Ansorena; Jose Luis Lanciego; María Jose Blanco-Prieto; María S. Aymerich
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 678 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background:
Glial cell‐derived neurotrophic factor is a survival factor for dopaminergic neurons and a promising candidate for the treatment of Parkinson's disease. However, the delivery issue of the protein to the brain still remains unsolved. Our aim was to investigate the effect of long‐term delivery of encapsulated glial cell‐derived neurotrophic factor within microspheres.
Methods:
A single dose of microspheres containing 2.5 μg of glial cell‐derived neurotrophic factor was implanted intrastriatally in animals 2 weeks after a 6‐hydroxydopamine lesion.
Results:
The amphetamine test showed a complete behavioral recovery after 16 weeks of treatment, which was maintained until the end of the study (week 30). This effect was accompanied by an increase in dopaminergic striatal terminals and neuroprotection of dopaminergic neurons.
Conclusions:
The main achievement was the long‐term neurorestoration in parkinsonian animals induced by encapsulated glial cell‐derived neurotrophic factor, suggesting that microspheres may be considered as a means to deliver glial cell‐derived neurotrophic factor for Parkinson's disease treatment. © 2011 Movement Disorder Society
📜 SIMILAR VOLUMES
Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects approximately 1,000,000 Americans. The cause of the disease remains unknown. The histopathological hallmarks of the disease are dopaminergic striatal insufficiency secondary to a loss of dopaminergic neurons in the sub
## Abstract Glial cell line‐derived neurotrophic factor (GDNF) has been shown to be neuroprotective in animal models of the dopamine deficiency in Parkinson's disease. To examine the role of the extracellular signal‐regulated kinases 1 and 2 (ERK1/2) in this process, we infused a single dose of GDN
## Abstract Application of basic fibroblast growth factor (FGF‐2) to the optic nerve after axotomy promotes the survival of retinal ganglion cells (RGCs) in the frog __Rana pipiens__ and results in a rapid up‐regulation of brain‐derived neurotrophic factor (BDNF) and TrkB synthesis by the RGCs. Her